<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00152412</url>
  </required_header>
  <id_info>
    <org_study_id>A00385</org_study_id>
    <nct_id>NCT00152412</nct_id>
  </id_info>
  <brief_title>Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis</brief_title>
  <official_title>A 4 Week Open, Multi-center Study Evaluating the Safety of Levocetirizine 1.25 mg b.i.d. Given as 0.5 mg/mL Oral Solution in 2 to 6 Year-old Children Suffering From Allergic Rhinitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <brief_summary>
    <textblock>
      4 week open study to evaluate the safety of levocetirizine in young children (2 - 6 years)&#xD;
      suffering from allergic rhinitis. As secondary objective, this study will assess the efficacy&#xD;
      of the treatment by means of the T4SS (Total 4 symptoms scores of allergic rhinitis) and each&#xD;
      of the 4 individual rhinitis symptom scores&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess safety of levocetirizine 1.25 mg bid given as 0.5 mg/mL oral solution in 2 to 6 years old children suffering from allergic rhinitis over 4 weeks of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess efficacy of 1.25 mg levocetirizine 0.5 mg/mL oral solution bid in 2 to 6 years old children suffering from allergic rhinitis over 4 weeks by means of the T4SS and each of the 4 individual rhinitis</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe the serum concentration of levocetirizine after 1,3 and 6 hours following the last treatment intake</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Allergic Rhinitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine oral solution</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At Visit 1:&#xD;
&#xD;
               -  Male or female outpatients aged 2 to 6 years old.&#xD;
&#xD;
               -  Subjects suffering from allergic rhinitis (perennial and/or seasonal) and&#xD;
                  symptomatic as attested by the Daily Record Card (DRC).&#xD;
&#xD;
          -  At Visit 2:&#xD;
&#xD;
               -  Respected wash-out periods for the forbidden medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Presence of asthma requiring treatment by inhaled corticosteroids.&#xD;
&#xD;
               -  Atopic dermatitis or urticaria requiring antihistamine treatment or the&#xD;
                  administration of oral or topical corticosteroids, or any other disease requiring&#xD;
                  the administration of oral or topical corticosteroids, immunomodulatory drugs,&#xD;
                  anti-inflammatory, or cytotoxic drugs.&#xD;
&#xD;
               -  Use during the course of the study, or during the specific wash-out periods, of&#xD;
                  any of the following medications: intranasal or systemic corticosteroids (within&#xD;
                  7 days), ketotifen (within 7 days), nedocromil or cromoglicate (within 7 days),&#xD;
                  loratadine and desloratadine (within 7 days), other antihistamines (within 3&#xD;
                  days) or decongestants (per os, nasal spray, or drops - within 3 days), or any&#xD;
                  other concomitant medications that, in the opinion of the Investigator,&#xD;
                  interfered with the study.&#xD;
&#xD;
               -  Initiation or change of dose of an immunotherapy regimen during the course of the&#xD;
                  study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/A00385_CSS_20060721.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>August 25, 2014</last_update_submitted>
  <last_update_submitted_qc>August 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2014</last_update_posted>
  <keyword>Allergic Rhinitis, safety, levocetirizine, children</keyword>
  <keyword>Xyzal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levocetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

